I don't think it's about forgiving, he took a gamble and failed, the question is can he, or the company without him turn it around?
If the company's bought out now, it would be cheap, but most investors may get even, or close to it.
If they're not bought out, if more trials are run, if the data's looking good and this time they have plenty of it, the company could still be a big winner, but it will take several years.
Of course, there is another possible gamble. Bundle up all they have today and submit it to the FDA. Acceptance of that submission could bring us somewhere in the $5 to $10 range, and a little over 6 months later, by the PDUGA date, the FDA would tell the tale. It's been said the company has spoken with the FDA, while I believe Europe was thought to be the easier route, perhaps much has changed with all the changes at the FDA.
The question is, who makes the decision? Is Missling to remain and do it, or is it to be someone else? Missling is clearly a gambler, does the BOD want to gamble again, or would they want to take a more conservative route to success?
Gary
Market Data 
Markets 
AI
